Managers’ Transactions
Faron Pharmaceuticals Ltd.(“Faron” or the “Company”) Managers’ transactions Company announcement, 8 April 2022 at 5:45 PM (EET) / 3:45 PM (GMT) / 10:45 AM (EDT) TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces today that Dr Markku Jalkanen, Chief Executive Officer of the Company, acquired 25,000 ordinary shares in Faron at a volume weighted